ArticleCommunications biology2025
PfPI3K inhibition reversed artemisinin resistance by increasing ROS and ubiquitinated protein levels in Plasmodium falciparum.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Phosphatidylinositol-3-phosphate (PI3P) is the key mediator of resistance to artemisinin drugs (ARTs) and that phosphatidylinositol 3-kinase (PfPI3K) is a promising target for eliminating ARTs resistance. However, few studies investigated the PfPI3K inhibitors. Here we show combination treatment with a potential PfPI3K inhibitor (idelalisib, which effectively inhibit PfPI3K activity resulting the decline in PI3P level) and dihydroartemisinin (DHA) exerts synergistic antimalarial effects and reverse ARTs resistance. The decline in PI3P level inhibits reactive oxygen species (ROS) degradation (resulting in ROS accumulation, apoptosis of parasites and the accumulation of ubiquitinated proteins), downregulates the gene expression of molecular chaperones and increases eIF2α phosphorylation, which finally leads to a dysregulated antioxidant system and disrupted proteostasis in parasites, thereby increasing the sensitivity of the parasites to ARTs and reversing ARTs resistance. Our results indicated that targeting PfPI3K with idelalisib was a successful antimalarial strategy for further controlling the development of ART resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.